AWT-020 is under clinical development by Anwita Biosciences and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate ...
The trust was unaware it was the beneficiary until it was contacted by the Guernsey Press this week. AWT CEO Roland Gauvain confirmed the trust had not been consulted about this decision and had no ...